journal article·2026-10

A hybrid nanoadjuvant cascading activation of the cGAS-STING-IFN-Ⅰ pathway to enhance radio-immunotherapy

Zhaohui Jiang, Peng Zhang, Guangzu Cui, Yongting Liu, Xinwen Wang, Zaigang Zhou, Jiang Fei, Kailing Wang, Yin Li, Xiangyang Zhang, Hong Shen, Shan Zeng, Ying Han, Jianliang Shen

Biomaterials· Volume 333
Publisher page

Abstract

The cGAS-STING signaling pathway is crucial for radiotherapy (RT)-induced immune modulation. However, under hypoxic conditions, reduced DNA damage and enhanced DNA damage repair (DDR) lead to lower cytosolic double-stranded DNA (dsDNA) levels, making standard RT doses inadequate for sustained cGAS-STING activation, resulting in transient immune responses. In this study, we developed the As-Mn@MnO2@Alb nanosystem as a potent radiosensitizer and cGAS-STING pathway amplifier. Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels. Concurrently, degradable MnO2 releases Mn2+ in tumors, boosting cGAS recognition and sensitivity, while generating oxygen to alleviate hypoxia and improve RT efficacy. The synchronized delivery of Mn2+ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8+ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (81)

Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology10.6004/jnccn.2022.0051 ↗
3. The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications10.1186/s13045-025-01691-5 ↗
4. The balance of STING signaling orchestrates immunity in cancer10.1038/s41590-024-01872-3 ↗
5. Regulation of cGAS–STING signalling and its diversity of cellular outcomes
6. The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer10.1084/jem.20180139 ↗
7. Old dogs, new trick: classic cancer therapies activate cGAS10.1038/s41422-020-0346-1 ↗
8. The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity10.1111/imm.13592 ↗
9. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models10.1038/s41467-023-36523-y ↗
10. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions10.1158/1078-0432.CCR-14-2824 ↗
11. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
12. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade10.1126/scitranslmed.adk0642 ↗
13. Inflammatory microenvironment remodelling by tumour cells after radiotherapy10.1038/s41568-020-0246-1 ↗
14. Systemic immunity in cancer10.1038/s41568-021-00347-z ↗
15. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence10.1038/nrc3958 ↗
16. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer10.1038/s41392-020-0150-x ↗
17. Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells10.1016/j.ccell.2018.03.027 ↗
18. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity10.1038/ncomms15618 ↗
19. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy10.1186/s12943-025-02366-y ↗
20. An orally available non-nucleotide STING agonist with antitumor activity10.1126/science.aba6098 ↗
21. Immunotherapy with a sting10.1126/science.abc6622 ↗
22. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach10.1186/s12885-024-12884-5 ↗
23. Excellent early outcomes of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma in children: a multicenter nonrandomized controlled trial10.3727/096504021X16184815905096 ↗
24. Improved outcomes with induction chemotherapy combined with arsenic trioxide in stage 4 neuroblastoma: a case series10.1177/15330338211041454 ↗
25. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the children's oncology group AAML1331 trial10.1001/jamaoncol.2021.5206 ↗
26. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma10.1002/cncr.29456 ↗
27. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB10.1038/sj.onc.1208192 ↗
28. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone10.1158/1535-7163.MCT-08-0287 ↗
29. Radiosensitivity enhancement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line10.7314/APJCP.2012.13.4.1693 ↗
30. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/akt and ERK1/2 signaling pathways10.4161/auto.5.4.7759 ↗
31. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma10.1016/j.ijrobp.2005.12.015 ↗
32. Molecular mechanisms of arsenic-induced disruption of DNA repair10.1021/acs.chemrestox.9b00464 ↗
33. Arsenic affects homologous recombination and single‐strand annealing but not end‐joining pathways during DNA double‐strand break repair10.1111/febs.16922 ↗
34. Nanodelivery of arsenic trioxide induces macrophage-governed cGAS-STING signaling to remodel immune microenvironment in hepatocellular carcinoma
35. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma10.1038/s41419-024-06685-8 ↗
36. Metabolism, toxicity and anticancer activities of arsenic compounds10.18632/oncotarget.14733 ↗
37. Smart human‐serum‐albumin–As2O3 nanodrug with self‐amplified folate receptor‐targeting ability for chronic myeloid leukemia treatment10.1002/anie.201701366 ↗
38. Biodegradable hollow MnO2 decorated by carbon dots with cholesterol depletion capability for cascaded amplification of sono-immunotherapy10.1016/j.biomaterials.2025.123559 ↗
39. Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect10.1016/j.jconrel.2021.01.036 ↗
40. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses10.1016/j.immuni.2018.03.017 ↗
41. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy10.1038/s41422-020-00395-4 ↗
42. Biomineralized MnO2 nanoplatforms mediated delivery of immune checkpoint inhibitors with STING pathway activation to potentiate cancer radio-immunotherapy10.1021/acsnano.2c10352 ↗
43. A hybrid nanoadjuvant simultaneously depresses PD‐L1/TGF‐β1 and activates cGAS‐STING pathway to overcome radio‐immunotherapy resistance10.1002/adma.202304328 ↗
44. An immunocompetent hafnium oxide-based STING nanoagonist for cancer radio-immunotherapy10.1021/acsnano.3c09293 ↗
45. Dual‐heterojunctions with reversibly photoactivated structure shift alternately decode photocatalytic H2 burst and Cascade catalytic ROS birth to repress cancer
46. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy10.1016/j.jconrel.2022.08.054 ↗
47. Arginine‐loaded nano‐calcium‐phosphate‐stabilized lipiodol pickering emulsions potentiates transarterial embolization‐immunotherapy10.4028/b-XDTcg5 ↗
48. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma10.1038/s41419-024-06685-8 ↗
49. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells10.1080/2162402X.2018.1523097 ↗
50. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment10.1038/s41590-019-0561-4 ↗
51. Detection of immunogenic cell death and its relevance for cancer therapy10.1038/s41419-020-03221-2 ↗
52. Targeting innate immune pathways for cancer immunotherapy10.1016/j.immuni.2023.07.018 ↗
53. How chemokines organize the tumour microenvironment10.1038/s41568-023-00635-w ↗
54. Dendritic cells and cancer immunity10.1016/j.it.2016.09.006 ↗
55. Serum protein-based nanoparticles for cancer diagnosis and treatment10.1016/j.jconrel.2020.10.030 ↗
56. Dual-synergistic nanomodulator alleviates exosomal PD-L1 expression enabling exhausted cytotoxic T lymphocytes rejuvenation for potentiated iRFA-treated hepatocellular carcinoma immunotherapy10.1021/acsnano.4c11257 ↗
57. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma10.1200/JCO.20.00290 ↗
58. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial10.1001/jamaoncol.2019.1478 ↗
59. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy10.1016/j.ccell.2025.02.024 ↗
60. Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites10.1158/1078-0432.CCR-23-3206 ↗
61. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade10.1038/s41467-022-32645-x ↗
62. STING: a master regulator in the cancer-immunity cycle10.1186/s12943-019-1087-y ↗
63. A stimuli-responsive cuproptosis switch boosts persistent immunotherapy for tumor eradication
64. Biomineralized engineered bacterial outer membrane vesicles as cGAS-STING nanoagonists synergize with lactate metabolism modulation to potentiate immunotherapy10.1021/jacs.5c05148 ↗
65. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment10.1186/s12943-025-02380-0 ↗
66. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy10.1016/j.scib.2023.02.027 ↗
67. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration10.1038/s41565-022-01225-x ↗
68. Engineering radiosensitizer‐based metal‐phenolic networks potentiate STING pathway activation for advanced radiotherapy10.1002/adma.202105783 ↗
69. Bi2–x mn x O3 nanospheres engaged radiotherapy with amplifying DNA damage10.1021/acsami.3c06838 ↗
70. Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory10.1016/j.biomaterials.2023.122303 ↗
71. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity10.1016/j.jbc.2021.100523 ↗
72. Disrupting intracellular homeostasis by copper‐based nanoinducer with multiple enzyme‐mimicking activities to induce disulfidptosis‐enhanced pyroptosis for tumor immunotherapy
73. Near-infrared phosphorescent carbon dots for sonodynamic precision tumor therapy10.1038/s41467-022-33474-8 ↗
74. Single atom catalysts remodel tumor microenvironment for augmented sonodynamic immunotherapy10.1002/adma.202313670 ↗
75. Defect engineering of biodegradable sulfide nanocage sonozyme systems enables robust immunotherapy against metastatic cancers10.1002/adfm.202411064 ↗
76. Radiotherapy combined with immunotherapy: the dawn of cancer treatment10.1038/s41392-022-01102-y ↗
77. The abscopal effect: a sense of DNA damage is in the air10.1172/JCI148274 ↗
78. Using immunotherapy to boost the abscopal effect10.1038/nrc.2018.6 ↗
79. Radiation-induced amphiregulin drives tumour metastasis
80. Multi‐hierarchical fe single atom nanozymes with axially‐coordinated O‐fe‐N4 active centers reshape macrophage epigenetics against immunosuppression
81. Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis10.1136/jitc-2022-006516 ↗